Novo Nordisk Valuation
| NVO Stock | USD 66.45 1.29 1.98% |
At this time, the firm appears to be fairly valued. Novo Nordisk AS secures a last-minute Real Value of $65.21 per share. The latest price of the firm is $66.45. Our model forecasts the value of Novo Nordisk AS from analyzing the firm fundamentals such as Return On Equity of 0.81, current valuation of 299.55 B, and Profit Margin of 0.35 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Novo Nordisk's valuation include:
Price Book 13.2664 | Enterprise Value | Enterprise Value Ebitda 14.2688 | Price Sales 0.9913 | Forward PE 15.6495 |
Fairly Valued
Today
Please note that Novo Nordisk's price fluctuation is very steady at this time. Calculation of the real value of Novo Nordisk AS is based on 3 months time horizon. Increasing Novo Nordisk's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Novo Nordisk is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novo Stock. However, Novo Nordisk's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 66.45 | Real 65.21 | Target 101.52 | Hype 66.45 |
The intrinsic value of Novo Nordisk's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Novo Nordisk's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Novo Nordisk AS helps investors to forecast how Novo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novo Nordisk more accurately as focusing exclusively on Novo Nordisk's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Novo Nordisk's intrinsic value based on its ongoing forecasts of Novo Nordisk's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Novo Nordisk's closest peers.
Novo Nordisk Cash |
|
Novo Valuation Trend
Knowing Novo Nordisk's actual value is paramount for traders when making sound investment determinations. Using both Novo Nordisk's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Novo Nordisk Total Value Analysis
Novo Nordisk AS is now anticipated to have company total value of 299.55 B with market capitalization of 278.57 B, debt of 102.79 B, and cash on hands of 37.47 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Novo Nordisk fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
299.55 B | 278.57 B | 102.79 B | 37.47 B |
Novo Nordisk Investor Information
The company has Price/Earnings To Growth (PEG) ratio of 0.97. Novo Nordisk AS last dividend was issued on the 31st of March 2025. The entity had 2:1 split on the 20th of September 2023. Novo Nordisk AS may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.46 | 0.4419 |
|
| |||||
| Total Cash From Operating Activities | 127 B | 121 B |
|
| |||||
| Operating Income | 134.8 B | 128.3 B |
|
|
Novo Nordisk Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novo Nordisk has an asset utilization ratio of 62.35 percent. This suggests that the Company is making $0.62 for each dollar of assets. An increasing asset utilization means that Novo Nordisk AS is more efficient with each dollar of assets it utilizes for everyday operations.Novo Nordisk Ownership Allocation
Novo Nordisk AS maintains a total of 3.36 Billion outstanding shares. Roughly 89.73 % of Novo Nordisk outstanding shares are held by general public with 10.27 % by institutional investors. Please note that on April 15, 2025, Representative Byron Donalds of US Congress acquired under $15k worth of Novo Nordisk AS's common stock.Novo Nordisk Profitability Analysis
The company reported the last year's revenue of 290.4 B. Total Income to common stockholders was 100.99 B with profit before taxes, overhead, and interest of 246.84 B.Novo Nordisk Past Distributions to stockholders
About Novo Nordisk Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Novo Nordisk AS. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Novo Nordisk AS based exclusively on its fundamental and basic technical indicators. By analyzing Novo Nordisk's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Novo Nordisk's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Novo Nordisk. We calculate exposure to Novo Nordisk's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novo Nordisk's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 245.9 B | 258.2 B | |
| Pretax Profit Margin | 0.44 | 0.22 | |
| Operating Profit Margin | 0.44 | 0.46 | |
| Net Profit Margin | 0.35 | 0.37 | |
| Gross Profit Margin | 0.85 | 0.58 |
Novo Nordisk Quarterly Retained Earnings |
|
A single share of Novo Nordisk represents a small ownership stake in the entity. As a stockholder of Novo, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Novo Nordisk Dividends Analysis For Valuation
As of the 2nd of May 2025, Dividends Paid is likely to grow to about 46.3 B, while Dividend Yield is likely to drop 0.01. . At this time, Novo Nordisk's Retained Earnings are very stable compared to the past year. As of the 2nd of May 2025, Earnings Yield is likely to grow to 0.06, while Price Earnings Ratio is likely to drop 17.42.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 44.1 B | 46.3 B | |
| Dividend Yield | 0.02 | 0.01 | |
| Dividend Payout Ratio | 0.44 | 0.26 | |
| Dividend Paid And Capex Coverage Ratio | 1.27 | 1.26 |
There are various types of dividends Novo Nordisk can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Novo shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Novo Nordisk AS directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Novo pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Novo Nordisk by the value of the dividends paid out.
Novo Nordisk Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4.5 B | |
| Quarterly Earnings Growth Y O Y | 0.292 | |
| Forward Price Earnings | 15.6495 |
Novo Nordisk Current Valuation Indicators
Novo Nordisk's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Novo Nordisk's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Novo Nordisk, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Novo Nordisk's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Novo Nordisk's worth.When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.292 | Dividend Share 11.4 | Earnings Share 3.43 | Revenue Per Share | Quarterly Revenue Growth 0.301 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.